What Happened
- The Central Government announced a nationwide free HPV (Human Papillomavirus) vaccination programme for all girls aged 14 years across India, with the formal launch scheduled for February 28, 2026.
- The vaccine being deployed is Gardasil-4 (quadrivalent HPV vaccine), which will be administered as a single dose at designated government health facilities.
- The programme fulfils a commitment made in the Union Budget 2024 and aligns with the WHO's goal to eliminate cervical cancer as a public health threat by 2030.
- Delivery will be through Primary Health Centres (PHCs), Community Health Centres (CHCs), Sub-District and District Hospitals, and Government Medical Colleges; vaccination is voluntary (informed consent required).
- During a three-year catch-up phase, the government plans to vaccinate approximately 1.15 crore girls annually — nearly 2.6 crore doses by 2027.
Static Topic Bridges
Human Papillomavirus (HPV) — Pathogen and Disease Mechanism
HPV is a group of more than 200 related viruses, of which over 40 types can infect the genital tract. High-risk oncogenic strains — particularly HPV types 16 and 18 — are responsible for approximately 70% of all cervical cancers globally. Nearly 99% of all cervical cancer cases are attributable to persistent HPV infection, making it one of the few cancers with a clearly identified preventable infectious cause.
- HPV types 6 and 11: cause approximately 90% of genital warts (low-risk, non-cancerous)
- HPV types 16 and 18: high-risk oncogenic types; responsible for ~70% of cervical cancers in India
- Gardasil-4 (quadrivalent): targets HPV types 6, 11, 16, 18 — protects against both genital warts and the two most common cancer-causing types
- Cervarix (bivalent): targets only HPV 16 and 18 — being used in some other countries' national programmes
- Gardasil-9 (nonavalent): targets 9 types (6, 11, 16, 18, 31, 33, 45, 52, 58) — broadest protection; not yet in India's national programme
- WHO recommends a single-dose schedule for girls aged 9-14 as equally effective as multi-dose schedules (updated recommendation, 2022)
Connection to this news: India's programme uses Gardasil-4 with the WHO-recommended single-dose protocol for 14-year-old girls, prioritizing population-scale coverage over multi-dose complexity.
India's Cervical Cancer Burden and Public Health Framework
Cervical cancer is the second most common cancer among women in India. In 2022, India recorded an estimated 1,27,526 new cases and 79,906 deaths from cervical cancer. India alone accounts for over 25% of the global cervical cancer mortality burden. Despite this, national screening coverage is alarmingly low — only about 1.9% of women aged 30-49 undergo cervical cancer screening.
- India's current screening method: Visual Inspection with Acetic Acid (VIA) — adopted as primary screening method in 2016; low sensitivity
- The Universal Immunisation Programme (UIP), under which this HPV campaign is being integrated, was launched in 1985 and covers 12 vaccine-preventable diseases
- National Cancer Control Programme (NCCP): established in 1975-76; covers cancer awareness, early detection, and treatment; operated under the National Health Mission framework
- The new programme is framed under "Swastha Nari" — government's vision for women's preventive health
- Bhutan became the first developing country to include HPV vaccine in its national programme (2010); Australia targets elimination of cervical cancer by 2028
Connection to this news: The programme directly addresses the low screening-and-prevention coverage gap — shifting the strategy from treatment-heavy to prevention-first through mass vaccination.
Universal Immunisation Programme (UIP) and Health Infrastructure
The Universal Immunisation Programme (UIP) is one of the largest public health programmes in the world, covering approximately 2.67 crore newborns and 2.9 crore pregnant women annually. The programme is implemented by the Ministry of Health and Family Welfare under the National Health Mission (NHM).
- UIP launched: 1985 (expanded from EPI introduced in 1978)
- Nodal Ministry: Ministry of Health and Family Welfare
- Current vaccines in UIP: BCG, OPV, IPV, Hepatitis B, Pentavalent, Rotavirus, PCV, MMR, JE (in endemic areas), MR, Td — and now HPV
- Cold chain infrastructure: UIP relies on a cold chain system at national, state, district, and sub-centre levels — critical for HPV vaccine viability
- Article 21A and health: Right to health is read into Article 21 (Right to Life) by the Supreme Court in Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996); no explicit fundamental right to health exists in Part III
Connection to this news: Integrating HPV vaccination into UIP infrastructure — with its existing cold chain, ASHAs, and ANM network — enables scale. The challenge is reaching the 14-year-old girl cohort, which is older than the typical UIP target of infants.
WHO's Cervical Cancer Elimination Strategy
The World Health Organization launched its Global Strategy to Accelerate the Elimination of Cervical Cancer in 2020. It sets out three targets to be met by 2030 — collectively known as the "90-70-90" targets: 90% of girls fully vaccinated with HPV vaccine by age 15; 70% of women screened with a high-performance test by age 35 and again by 45; and 90% of women identified with cervical disease receiving treatment.
- WHO elimination threshold: fewer than 4 cases of cervical cancer per 100,000 women per year
- India's current rate: approximately 18 per 100,000 women (well above the elimination threshold)
- Global commitment: 2020 WHO strategy adopted by 194 Member States
- India's contribution: with ~1.27 lakh new cases/year, scaling up HPV vaccination and HPV-DNA screening are both required to approach WHO targets
Connection to this news: India's nationwide HPV vaccination launch is a direct step toward the WHO 90-70-90 target — specifically the 90% vaccination coverage goal for girls by age 15.
Key Facts & Data
- Target group: Girls aged 14 years (14-year birth cohort)
- Vaccine: Gardasil-4 (quadrivalent) — single dose
- Annual target: 1.15 crore girls per year; ~2.6 crore doses by 2027
- Launch date: February 28, 2026
- Annual cervical cancer deaths in India: ~42,000-79,906 (varies by estimate)
- New cases per year in India: ~1.27 lakh (2022 data)
- India's share of global cervical cancer mortality: over 25%
- WHO elimination threshold: fewer than 4 cases per 1,00,000 women per year
- National screening coverage (current): only 1.9% of women aged 30-49
- HPV types covered by Gardasil-4: types 6, 11, 16, 18
- HPV types 16 and 18 together cause: ~70% of cervical cancers in India
- Programme origin: Union Budget 2024 commitment; integrated into UIP